Podcast Summary: FDA’s ENG Label Change – What To Know

Podcast: Dr. Chapa’s OBGYN Clinical Pearls
Host: Dr. Chapa
Date: January 23, 2026

Episode Overview

This episode is a rapid, evidence-based rundown aimed at OBGYN providers about the FDA’s label update for the etonogestrel implant (Nexplanon) from three to five years of approved use. Dr. Chapa highlights the clinical data driving this change, addresses skeptics of off-label recommendations, and provides guidance about updated practice logistics, including a new REMS (Risk Evaluation and Mitigation Strategy) requirement. The episode is informative, engaging, and packed with clinical pearls for current and future contraceptive care.

Key Discussion Points and Insights

1. Background on Etonogestrel (Nexplanon) Implant

• Dr. Chapa's longstanding support:
  “I am a little bit of a fan of the EternalGestrel implant for contraception, for menstrual suppression, for chronic pelvic pain. It just works really well.” [01:08]
• History:
  Recaps the progression from Norplant (multiple capsules, challenging removal), to Implanon (single rod, 2006), to radiopaque Nexplanon (2010).
• Original label:
  Approved for 3 years, despite mounting real-world and clinical trial evidence suggesting 5-year efficacy.
• Off-label frustrations:
  “Every time I’ve said that, somebody sends me a message... ‘What if a pregnancy happens after five years—are you going to go and defend them?’ Yes, I’ve received those messages.” [01:48]

2. Clinical Data Driving the Label Change

• Evidence preceded approval:
  “It's interesting because sometimes the FDA releases something or approves something, then the clinical data builds on that. In this case, it was the reverse.” [02:27]

• Peer-reviewed studies:

  • Prospective study: 390 women past 3 years up to 5 years.

    “Overall 5-year, the Kaplan-Meier cumulative pregnancy rate was 0.6 per 100 woman-years...There was no additional pregnancies recorded [in the additional two years]. It was phenomenal.” [07:18]

  • Contraceptive CHOICE Project: Nearly 300 users beyond 3 years, 0 pregnancies per 100 woman-years in years four and five.

• Pharmacokinetic support:

  • Suppressive hormone levels well above threshold at years 4 and 5:

    “You need around 90 picograms per milliliter...in year four and five, there were well over 150.” [08:55]

• Key FDA trial:

  • Registration number: NCT 0462-6596.
  • Design: Multicenter, single-arm, open-label.
  • 399 women enrolled, allowed to continue implant past original 36 months.
  • Results: No pregnancies in years 4 or 5.
  • Inclusion of women with BMI >30 (38%) and >40 (10%): No loss of efficacy.

    “No pregnancies were recorded in years four and five. None.” [10:32]

  • Reported Pearl Index:

    “This is the official Pearl index of 0.0 pregnancies per 100 woman years. What?! I mean, it’s insane.” [11:04]

3. FDA Approval and Clinical Practice Updates

• Label extension:
  As of January 2026, legal duration officially increased to 5 years.
• REMS program:
  • New requirement: All prescribers need to re-register with the manufacturer under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) by February 23, 2026.

    “You may have to re-register with them, because they are launching a new REMS database for this...just one more thing we have to do. You gotta register by the end of February.” [06:52]

• Providers’ practical response:

  “If a patient asks you, ‘Is it safe? Can I go to five years?’ You go, ‘Yep. If you choose to, you can.’” [05:13]

• Similarities with IUD label evolutions:

  “This is very similar to the Mirena story. Remember, Mirena was like five years and then miraculously went to seven years—nothing changed except the label.” [12:31]

4. Dr. Chapa’s Tone and Key Message

• Playful vindication:
  Jokes throughout about prior criticisms and being “right all the time” (recurring soundbites).

  “Boy, do I hate being right all the time” [Multiple, 02:11, 04:15, 04:30, 05:13, 06:33]

• Reassuring attitude:
  Encourages providers not to worry about the REMS change and underscores that updated guidance is entirely data-driven.
• Bottom line:
  The Nexplanon implant is now FDA-approved for 5 years of use, and the data is “astonishingly strong.”

Notable Quotes & Memorable Moments

• [01:08] Dr. Chapa:
  “I am a little bit of a fan of the EternalGestrel implant for contraception, for menstrual suppression, for chronic pelvic pain. It just works really well.”
• [02:27] Dr. Chapa:
  “It's interesting because sometimes the FDA releases something or approves something, then the clinical data builds on that. In this case, it was the reverse.”
• [04:18] Dr. Chapa:
  “The data was there and I said on various podcast episodes in the past, the label will change. We just gotta wait for it.”
• [08:55] Dr. Chapa:
  “In general, you need around 90 picograms per milliliter of this hormone for suppression. And in year four and five, there were well over 150.”
• [11:04] Dr. Chapa:
  “This is the official Pearl index of 0.0 pregnancies per 100 woman years. What? I mean, it’s insane.”
• [12:31] Dr. Chapa:
  “This is very similar to the Mirena story. Remember, Mirena was like five years and then miraculously went to seven years and then a competitor came about and miraculously went to eight years. Nothing changed—just the label.”

Important Timestamps

| Timestamp | Segment/Topic |
|-----------|----------------|
| 01:08 | Dr. Chapa introduces episode, personal connection to ENG implant |
| 02:27 | Explanation of evidence preceding FDA action |
| 04:18 | Comments on previous predictions about label changing |
| 06:52 | Announcement and details of upcoming REMS re-registration requirement |
| 07:18 | Key findings from 5-year efficacy studies |
| 08:55 | Discussion of hormone levels and pharmacokinetic data |
| 10:32 | Official FDA trial findings: no pregnancies in years 4 and 5 |
| 11:04 | Pearl Index “0.0” per 100 woman-years emphasized |
| 12:31 | Comparison of ENG extension to Mirena history |

Clinical Pearls & Takeaways

• Nexplanon (etonogestrel) is now FDA-approved for 5 years of use.
• Clinical and pharmacological data robustly support efficacy through year 5—including in women with higher BMIs.
• Pearl Index of 0.0 in years 4 and 5: “astonishing” protection.
• Providers must re-register for a REMS program by Feb 23, 2026, to maintain access to the device.
• Advise patients they may confidently use the device for 5 years, not just 3.

Conclusion

Dr. Chapa delivers clear, practical, and empirically grounded guidance on the FDA’s new duration for the etonogestrel implant, interwoven with humor and candor. This episode empowers providers to confidently advise and manage patients using Nexplanon for up to five years, backed by both official FDA approval and “rockstar” supporting data.